Rosuvastatin Placebo

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, AstraZeneca AB, Yuhan Corporation

Conditions

HypercholesterolaemiaHyperlipidemiaHypertension

Phase 3

Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

CompletedNCT01914432

Yuhan CorporationHyperlipidemia, Hypertension

Start: 2013-11-30End: 2014-06-30Updated: 2014-07-08

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia

RecruitingCTIS2025-521495-54-00

Merck Sharp & Dohme LLCHyperlipidemia

Start: 2025-12-20Target: 110Updated: 2025-12-04

A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared with Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients with Hypercholesterolaemia.

Not yet recruitingCTIS2026-526258-15-00

AstraZeneca ABHypercholesterolaemia

Target: 60Updated: 2026-08-17

Related Papers

Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study.

2018-04-1722 citations